Team 19

Assessing Care Models and Policies Implemented in Primary Health Care for Persons with Neurocognitive Disorders

To see how we evaluated these models and initiatives, see our research objectives and methods

Our work has long lasting impacts on clinicians, persons living with dementia and caregivers:

  1. Through several media interviews, articles appearing in the press and other lay publications we have contributed to general public awareness
    View Media Section
  2. We have engaged with clinicians to:
    • Increase the knowledge and ability to care for people with dementia, especially in primary care.
    • Make improvements in access, quality, and continuity of care for people with dementia.
    • Facilitate collaboration between primary care clinicians and specialists around dementia care.
  3. We have influenced several provincial and federal policies when it comes to strategies for scaling-up initiatives across Canada:Our results were used by the Canadian Academy of Health Sciences (CAHS) during the panel requested by the Public Health Agency of Canada (PHAC) to examine the evidence available to support recent legislation creating a national strategy on dementia. These results continue to be used.
    • The PHAC requested the CAHS to put together a report on available evidence 3 of our team members participated on the CAHS panel, plus results.
      View the CAHS Report
    • PHAC continues to use our results in writing their national strategy on dementia.

Preliminary Results, News and Program Updates

Results:

Preliminary results in Quebec suggest that the Alzheimer Plan has had a beneficial impact on the quality of primary care for persons living with dementia and their caregivers. These results could be explained by the positive attitudes, practices, knowledge and competencies to detect, diagnose, treat and follow-up persons living with dementia in Family Medicine Groups.

Finally, preliminary analyses suggest that the following elements must be present for the successful implementation of best practices: training and mentoring to clinicians; clinical tools; accompaniment by change managers; and identification of champions, case management mostly in the form of a dyad: physician-and-nurse. We have also been able to identify innovative practices that need to be scaled-up during phase 2.

Featured Results:

Dec ROSA KT

    Mar 2022 ROSA KT

 

Executive Summary:

View the executive summary from our latest report to the Ministère du Santé et Services Sociaux du Québec (Quebec Ministry of Health).
English Executive SummaryFrench Executive Summary

Program Updates:

News:

To keep up-to-date on the latest news, follow @equipeROSAteam and check the #ROSAteam and #équipeROSA tags on Twitter!

06/07/2019PROVINCIAL COUNCIL STAKEHOLDER MEETING

Stakeholders from Quebec, Ontario, New Brunswick and Alberta, including decision-makers, managers, researchers, and patient and caregiver representatives, were invited to a meeting in Montreal, Canada on June 7th 2019. This full day meeting featured updates on the current state of the ROSA research program in Ontario, Quebec and New Brunswick, as well as on federal initiatives (Canadian Academy of Health Sciences report and Public Health Agency of Canada progress report on the Federal Dementia Strategy). Discussion centered around the use of interdisciplinary primary care teams, the integration of AD evaluation results into policy, and the use and accessibility of community services and resources.
View More Events

03/22/2019CCNA PHASE TWO FUNDING

Today, the Government of Canada announced the next phase of funding for the Canadian Consortium on Neurodegeneration in Aging (CCNA). From 2019 to 2024, CCNA will receive $46 million from the Canadian Institutes of Health Research (CIHR) and 11 other partner organizations, including the Alzheimer Society of Canada (ASC), and the Fonds de recherche du Québec – Santé (FRQS). Our research team ROSA (Research on Organization of Healthcare Services for Alzheimers), co-led by Drs. Howard Bergman and Isabelle Vedel continue investigating how to provide innovative care for persons living with dementia. Stay tuned as we unveil the new set of research objectives and methods in the coming months.

01/17/2019CAHS REPORT

Recognizing the importance of developing and implementing an effective strategy to address this challenge, the Minister of Health of Canada, through the Public Health Agency of Canada, asked the Canadian Academy of Health Sciences (CAHS) to provide an evidence-informed and authoritative assessment on the state of knowledge to help advance federal priorities under the National Strategy for Alzheimer’s Disease and Other Dementias Act.

To address the charge, the CAHS assembled a multidisciplinary, multi-sectoral panel of six experts with a range of expertise, experience, and demonstrated leadership in this domain, including several members of the ROSA team.
See More

 

Publication List and Media

Publications:

Media:

OUR TEAM

see the full ROSA team organigram

Principal Investigators:

Dr. Howard Bergman

McGill University

View Bio

Dr. Isabelle Vedel

McGill University

View Bio

Co-Principal Investigators:

Susan Bronskill

Institute for Clinical Evaluative Sciences

View Bio

Carrie McAiney

University of Waterloo

View Bio

Tibor Schuster

McGill University

View Bio

Yves Couturier

Université de Sherbrooke

View Bio

Pam Jarrett

Dalhousie University

View Bio

Shelley Doucet

University of New Brunswick

View Bio

Laura Middleton

University of Waterloo

View Bio

Clare Liddy

University of Ottawa

View Bio

Heather Keller

University of Waterloo

View Bio

Samira Abbasgholizadeh Rahimi

McGill University

View Bio

Claire Godard-Sebillotte

McGill University Health Centre

The following page is authored by members of Team 19 of the Canadian Consortium on Neurodegeneration in Aging. Any questions regarding the content can be directed to: rosa-admin.fammed@Mcgill.ca

Go back to top